Medroxyprogesteronum [Inn-Latin] en es it fr

Medroxyprogesteronum [Inn-Latin] Brand names, Medroxyprogesteronum [Inn-Latin] Analogs

Medroxyprogesteronum [Inn-Latin] Brand Names Mixture

  • Lunelle (Medroxyprogesterone + Estradiol)

Medroxyprogesteronum [Inn-Latin] Chemical_Formula


Medroxyprogesteronum [Inn-Latin] RX_link

Medroxyprogesteronum [Inn-Latin] fda sheet

Medroxyprogesteronum_[Inn-Latin] FDA

Medroxyprogesteronum [Inn-Latin] msds (material safety sheet)

Medroxyprogesteronum [Inn-Latin] Synthesis Reference

P. Ruggieri, C. Ferrari, U.S. Pat. 3,043,832 (1962)

Medroxyprogesteronum [Inn-Latin] Molecular Weight

344.488 g/mol

Medroxyprogesteronum [Inn-Latin] Melting Point

220 - 223.5 oC

Medroxyprogesteronum [Inn-Latin] H2O Solubility


Medroxyprogesteronum [Inn-Latin] State


Medroxyprogesteronum [Inn-Latin] LogP


Medroxyprogesteronum [Inn-Latin] Dosage Forms

Tablets; Depo injection

Medroxyprogesteronum [Inn-Latin] Indication

Used as a contraceptive and to treat amenorrhea, abnormal uterine bleeding, endometriosis, endometrial and renal cell carcinomas, and pulmonary disorders such as chronic obstructive pulmonary disease (COPD), Pickwickian syndrome, and other hypercapnic pulmonary conditions.

Medroxyprogesteronum [Inn-Latin] Pharmacology

Medroxyprogesterone is a synthetic progestin more potent than progesterone.

Medroxyprogesteronum [Inn-Latin] Absorption

Rapidly absorbed from GI tract

Medroxyprogesteronum [Inn-Latin] side effects and Toxicity

Side effects include loss of bone mineral density, BMD changes in adult women, bleeding irregularities, cancer risks, and thromboembolic disorders.

Medroxyprogesteronum [Inn-Latin] Patient Information

Medroxyprogesteronum [Inn-Latin] Organisms Affected

Humans and other mammals